Prevalence of antiphospholipid antibodies in patients with sterility undergoing ‘in vitro’ fertilization
M. Proietta,S. Ferrero,F. Del Porto
DOI: https://doi.org/10.1177/0961203314525865
IF: 2.858
2014-06-01
Lupus
Abstract:Sir, Sterility and infertility are related to several hormonal, genetic, anatomical and immunological causes; however, in about 15% of couples sterility/ infertility remain unexplained. Antiphospholipid antibodies (aPL), which include anti-cardiolipin antibodies (aCL), anti-b2-glycoprotein-1 antibodies (ab2GPI) and lupus anticoagulant (LA), are known to be responsible for a wide spectrum of pregnancy disorders which have been classified in the antiphospholipid syndrome (APS) criteria, but their relationship with sterility/infertility is under debate. Recently it has been reported that autoimmunity may represent a cause of unexplained infertility and non-chromosomal recurrent miscarriage, so that early diagnosis and treatment of immunological causes is recommended in couples with sterility/infertility. We therefore retrospectively evaluated the prevalence of aCL, ab2GPI and LA in a population of women with apparently unexplained sterility undergoing in vitro fertilization. From the clinical records of 240 patients undergoing in vitro fertilization during a period ranging from September 2012 to March 2013, we selected 25 women with sterility and positive aPL and/or antinuclear antibodies (ANA). Among these, seven were excluded because negative LA and very low titres of aPL (<20 GPL/MPL) were found, and three were excluded because a cause of sterility was diagnosed: one had an autoimmune thyroiditis, one an autoimmune polyendocrinopathy with premature menopause and one a polycystic ovary syndrome. Therefore 15 women with unexplained sterility and evidence of persisting positive aPL at the pre-fertilization screening were finally selected. No patients had known causes of sterility or history of autoimmune diseases. In each woman aCL, ab2GPI, LA, ANA and extractable nuclear antigens (ENA) were evaluated. The results are summarized in Table 1. All patients had positive aPL at titres >20 GPL/ MPL. In particular, seven women had positive aCL IgM: 2/7 had titres >100 MPL, 4/7 titres between 30 and 40 MPL, and 1/7 titres of 25 MPL. Two women had positive aCL IgG: 1/2 had titres of 45 GPL, and 1/2 titres of 25 GPL. One woman had ab2GPI IgG at a titre >20 GPL, and one patient had ab2GPI IgG at titre 15 GPL and positive LA. All nine women with positive ANA displayed titres ranging from 1:80–1:640. One patient had positive SS-A. Our results demonstrated that the prevalence of aPL in a population of women with apparently unexplained sterility undergoing in vitro fertilization is higher than that observed in the general population. In our sterile patients, indeed, positive aPL were observed in 6.25% of the women, whereas in the general population the prevalence is about 2%. Moreover, in 53.33% of the cases a diagnosis of APS was made. This high prevalence of aPL in our population seems to suggest that these auto-antibodies may account at least in part for the unexplained sterility, probably also by causing very early recurrent abortions. However, the relationship between aPL and sterility is still under debate. Recently, indeed, it has been reported that prothrombotic conditions, including APS, are not related to reproductive failure. However, most studies have demonstrated that unexplained infertility occurs mainly in patients with positive auto-antibodies, including aPL and ANA. Accordingly, in our series 60% of the aPL-positive patients showed also positive ANA, and 26.66% of women fulfilled classification criteria for systemic lupus erythematosus (SLE), strongly supporting the hypothesis of an immunological contribution to sterility. Interestingly the four patients with SLE, after appropriate treatment, experienced full-term pregnancy. This observation is in agreement with the literature, where it has been reported that treating autoimmune co-morbidities ameliorates implantation rates in women undergoing in vitro fertilization. We therefore recommend that auto-antibodies be assessed in all women with unexplained sterility undergoing in vitro fertilization, since women without major organ involvement may be unaware of a hidden autoimmune disease. Diagnosis and treatment of unknown systemic autoimmune conditions seem to represent critical objectives in all women who want to conceive, not only regarding implantation rate, but also considering that aPL may lead to pregnancy Correspondence to: Flavia Del Porto, Dipartimento di Medicina Clinica e Molecolare, Facoltà di Medicina e Psicologia, ‘‘Sapienza’’, Università di Roma, Azienda Ospedaliera Sant’Andrea, Via di Grottarossa 1035-1039, 00189 Rome, Italy. Email: flavia.delporto@uniroma1.it Received 24 July 2013; accepted 4 February 2014